Samples Procurement for Colorectal Cancer, Gastric Cancer, and Non-malignant Disease
Samples Procurement for Patients With Colorectal Cancer, Gastric Cancer, and Non-malignant Disease Undergoing Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tao Fu, MD
- Phone Number: +8613720120190
- Email: tfu001@whu.edu.cn
Study Locations
-
-
Hubei
-
Wuhan, Hubei, China, 430060
- Recruiting
- Department of Gastrointestinal Surgery II, Renmin Hospital of Wuhan University
-
Contact:
- Tao Fu, MD
- Phone Number: 86-13720120190
- Email: futao1975@tom.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Any patient diagnosed with colorectal cancer, gastric cancer, non-malignant disease that requires undergoing surgery.
- Must be willing and able to provide informed consent.
Exclusion Criteria:
- Subjects whose comorbidities would preclude diagnostic or therapeutic intervention.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Colorectal cancer or gastric cancer patient
Patients suffering from CRC or gastric cancer scheduled to have surgical resection of colon/rectum or stomach.
|
Samples are collected at the time of a scheduled surgery that is part of normal treatment.
This study will not have any impact on the care or treatment the patient receives.
|
|
Non-malignant disease patient
Patients suffering from non-malignant disease scheduled to have surgery.
|
Samples are collected at the time of a scheduled surgery that is part of normal treatment.
This study will not have any impact on the care or treatment the patient receives.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Confirmation of diagnosis by pathologist
Time Frame: Up to 3 years
|
Once tissue is collected, those samples that have a confirmed diagnosis of disease by the pathologist will be used.
|
Up to 3 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Tao Fu, MD, Renmin Hospital of Wuhan University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Gastroenteritis
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Stomach Neoplasms
- Colorectal Neoplasms
- Inflammatory Bowel Diseases
- Stomach Ulcer
- Hemorrhoids
Other Study ID Numbers
Other Study ID Numbers
- SAMPGICUS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.